Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results

被引：8
|
作者：
Kim, Y. H.
Sasaki, Y.
Lee, K. H.
Rha, S. Y.
Park, S.
Boku, N.
Komatsu, Y.
Kim, T.
Kim, S.
Sakata, Y.
机构：
[1] Korea Univ, Coll Med, Seoul 136705, South Korea
[2] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[3] Yeungnam Univ Hosp, Taegu, South Korea
[4] Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Shizuoka Canc Ctr, Shizuoka, Japan
[7] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
[8] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[9] Kyung Hee Univ Hosp, Seoul, South Korea
[10] Misawa Municipal Hosp, Misawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.87
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
87
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
    Sym, Sun Jin
    Hong, Junshik
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Park, Yeon Ho
    Lee, Woon Ki
    Chung, Min
    Kim, Hyung-Sik
    Park, Se Hoon
    Shin, Dong Bok
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 481 - 488
  • [42] 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) plus bevacizumab in patients with metastatic colo-rectal cancer: Preliminary results of a phase II trial
    Condorelli, S.
    Cordio, S.
    Rosati, G.
    Caputo, G.
    Rampello, E.
    Salice, P.
    Parra, H. J. Soto
    Tondulli, L.
    Pumo, V.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2007, 18 : 8 - 8
  • [43] Oxaliplatin-hased regimen as neoadjuvant chemotherapy for Chinese patients with advanced gastric cancer: Preliminary results of a phase II study
    Ji, JF
    Yu, Z
    Zhong, XN
    Wu, XJ
    Wu, Q
    Bu, ZD
    Wang, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 359S - 359S
  • [44] Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
    Aparicio, J
    Vicent, JM
    Maestu, I
    Garcerá, S
    Busquier, I
    Bosch, C
    Llorca, C
    Díaz, R
    Fernández-Martos, C
    Galán, A
    ANNALS OF ONCOLOGY, 2003, 14 (07) : 1121 - 1125
  • [45] Phase II study of irinotecan plus leucovorin and bolus 5 fluorouracil as first or second line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma
    Gerolymos, M.
    Koutras, A.
    Kontogeorgou, E.
    Iconomou, G.
    Vourli, G.
    Tsiata, E.
    Makatsoris, T.
    Chrysanthopoulos, C.
    Kalofonos, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
    Wang, Jinwan
    Xu, Ruihua
    Li, Jian
    Bai, Yuxian
    Liu, Tianshu
    Jiao, Shunchang
    Dai, Guanghai
    Xu, Jianming
    Liu, Yunpeng
    Fan, Nanfeng
    Shu, Yongqian
    Ba, Yi
    Ma, Dong
    Qin, Shukui
    Zheng, Leizhen
    Chen, Weichang
    Shen, Lin
    GASTRIC CANCER, 2016, 19 (01) : 234 - 244
  • [47] Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
    Jinwan Wang
    Ruihua Xu
    Jian Li
    Yuxian Bai
    Tianshu Liu
    Shunchang Jiao
    Guanghai Dai
    Jianming Xu
    Yunpeng Liu
    Nanfeng Fan
    Yongqian Shu
    Yi Ba
    Dong Ma
    Shukui Qin
    Leizhen Zheng
    Weichang Chen
    Lin Shen
    Gastric Cancer, 2016, 19 : 234 - 244
  • [48] Irinotecan, leucovorin and 5-fluorouracil (ILF) versus ILF plus cisplatin (PILF) for advanced gastric cancer: Interim analysis from a randomized phase II trial
    Shin, Dong Bok
    Park, Se Hoon
    Nam, Eunmi
    Cho, Eun Kyung
    Lee, Jae Hoon
    ANNALS OF ONCOLOGY, 2006, 17 : 312 - 312
  • [49] A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer
    Boukovinas, I.
    Androulakis, N.
    Polyzos, A.
    Vardakis, N.
    Amarantidis, K.
    Bozionelou, V.
    Kouroussis, C.
    Giassas, S.
    Christophyllakis, C.
    Mavroudis, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results
    Ibrahim, N. K.
    Wong, L.
    Rosen, L.
    Shan, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345